Dechert LLP advised 4SC AG in a cross-border licensing and development partnership with Guangzhou LingSheng Pharma Tech Co., Ltd (Link Health). The partnership agreement, developed for rights involving cancer compound 4SC-205, provides Link Health with exclusive licensing rights for the development and marketing of the compound in China, Hong Kong, Taiwan, and Macao. Link Health will have the responsibility of performing and financing the clinical development of the compound.

4SC is a biotechnology company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs, headquartered in Germany. In exchange for the rights to 4SC-205, 4SC will receive compensation totaling up to €76 million from Link Health in upfront and milestone payments, which they will receive following specified development, regulatory and commercialization.

The Dechert team advising 4SC AG included Frankfurt-based lead partner Dr. Rüdiger Herrmann and international counsel Alicia Hong from the firm’s Corporate and Securities practice group. The team’s previous advice to 4SC included the representation on its licensing and development partnership with Singapore-based company Menarini Asia-Pacific Holdings Pte. Ltd.